GSK1223249

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Amyotrophic Lateral SclerosisMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Phase 1

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

CompletedNCT00875446

GlaxoSmithKlineAmyotrophic Lateral Sclerosis

Start: 2009-05-13End: 2011-09-09Updated: 2017-09-20

NOGO-A in Multiple Sclerosis FTIH

TerminatedNCT01424423

GlaxoSmithKlineMultiple Sclerosis

Start: 2010-02-11End: 2010-08-26Updated: 2017-09-20

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

TerminatedNCT01435993

GlaxoSmithKlineMultiple Sclerosis, Relapsing-Remitting

Start: 2011-09-08End: 2012-01-23Updated: 2020-11-24

Related Papers

Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.

2014-05-1938 citations